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Abstract
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Following focal cerebral ischemia, blood vessels in the ischemic border, or penumbra, launch an
angiogenic response. In light of the critical role for fibronectin in angiogenesis, and the
observation that fibronectin and its integrin receptors are strongly upregulated on angiogenic
vessels in the hypoxic CNS, the aim of this study was to establish whether angiogenic vessels in
the ischemic CNS also show this response. Focal cerebral ischemia was established in C57/Bl6
mice by middle cerebral artery occlusion (MCA:O), and brain tissue analyzed seven days
following re-perfusion, a time at which angiogenesis is ongoing. Within the ischemic core,
immunofluorescent (IF) studies demonstrated vascular expression of MECA-32, a marker of leaky
cerebral vessels, and vascular breakdown, defined by loss of staining for the endothelial marker,
CD31, and the vascular adhesion molecules, laminin, dystroglycan and α6 integrin. Within the
ischemic penumbra, dual-IF with CD31 and Ki67 revealed the presence of proliferating
endothelial cells, indicating ongoing angiogenesis. Significantly, vessels in the ischemic penumbra
showed strong upregulation of fibronectin and the fibronectin receptors, α5β1 and αvβ3 integrins.
Taken together with our recent finding that the α5β1 integrin plays an important role in promoting
cerebral angiogenesis in response to hypoxia, these results suggest that stimulation of the
fibronectin-α5β1 integrin signalling pathway may provide a novel approach to amplifying the
intrinsic angiogenic response to cerebral ischemia.
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INTRODUCTION
Neurons in the central nervous system (CNS) are acutely sensitive to loss of oxygen and
glucose, and if starved of these nutrients for even minutes, embark on a pathway of cell
death (Dirnagl et al. 1999). The current consensus is that once this destructive pathway is
initiated, it continues in an irreversible manner, resulting in wholesale loss of neurons and
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the well-described clinical hallmarks of stroke: aphasia, paralysis or even death (Sharp et al.
2000). While the clinical defect is ultimately caused by death of neurons and associated glial
cells, cerebral ischemia also affects the function and integrity of vascular cells, which in
itself, can lead to exacerbation of neuronal death (del Zoppo and Hallenbeck 2000). Shortly
following the ischemic insult, cerebral vessels in the ischemic core start to lose their
permeability barrier (Hamann et al. 1996), due to loss of endothelial tight junction proteins
(Yang et al. 2007). At the same time, extracellular matrix (ECM) proteins in the vascular
basal lamina are degraded (Hamann et al. 1995), and endothelial cells and astrocytes lose
expression of ECM receptors , resulting in their uncoupling from the vascular basement
membrane and cell death (Tagaya et al. 2001; Tagaya et al. 1997; Wagner et al. 1997). This
combination of events leads to vessel breakdown, and secondary expansion of the ischemic
infarct.
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While ischemia has catastrophic consequences for cerebral vessels within the ischemic core,
evidence suggests that the milder ischemic stimulus experienced in the ischemic periphery,
or penumbra, actually promotes angiogenic remodeling, such that 4-7 days after the
ischemic insult, new sprouting capillaries can be seen (Chen et al. 1994; Hayashi et al. 2003;
Wei et al. 2001). This has led to the suggestion that stimulation or amplification of this
endogenous response could be exploited as a means of encouraging new blood vessel
formation in cerebral areas susceptible to ischemia, either before, or immediately after an
ischemic event (Greenberg and Jin 2005).
In trying to define the molecular mechanisms that regulate cerebral angiogenesis, studies
have revealed a role for specific transcription factors, including hypoxia inducible factor-1α
(HIF-1α) (Chavez et al. 2000) and the Hox family (Chen et al. 2004), growth factors,
including vascular endothelial growth factor (VEGF) (Kuo et al. 1999), and the
angiopoietins (Ang1 and Ang2) (Pichiule and LaManna 2002). In addition, ECM proteins
also play important roles in regulating vascular growth and remodeling. Specifically,
fibronectin promotes angiogenesis, both during development and in physiological and
pathological remodeling events in the adult (Astrof and Hynes 2009). Null mutations in the
fibronectin gene or its main cell surface receptors, the α4, α5 or αv integrins, show major
defects in developmental angiogenesis, leading to embryonic or postnatal lethality (Bader et
al. 1998; George et al. 1993; Yang et al. 1993; Yang et al. 1995). An angiogenic role for
fibronectin is further suggested by the observations that fibronectin and its specific integrin
receptors are expressed at only low levels in quiescent vessels, but strongly upregulated in
developmental or tumor-associated angiogenic vessels (Kim et al. 2000; Risau and Lemmon
1988; Tonnesen et al. 1985).
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Studies of cerebral angiogenesis are largely consistent with these findings, with fibronectin
and its integrin receptors expressed at high levels by angiogenic vessels in the developing
brain, but then downregulated with maturation (Dummula et al. 2010; Milner and Campbell
2002). To determine whether this developmental program is recapitulated during
angiogenesis in the adult CNS, we recently examined this process in a mouse model of
cerebral hypoxia, in which a strong physiological angiogenic response occurs. This revealed
strong induction of fibronectin and the two fibronectin receptors, α5β1 and αvβ3 integrins
on angiogenic vessels (Li et al. 2010; Milner et al. 2008a). More recently, we have
demonstrated the functional significance of these interactions, by showing that mice
deficient in endothelial cell expression of the α5 integrin, show an attenuated angiogenic
response to chronic cerebral hypoxia (Li et al, manuscript in preparation). Taken together,
this demonstrates that fibronectin promotes cerebral angiogenesis, via the α5β1 integrin.
Considering the potential clinical relevance of angiogenic vessels in the ischemic penumbra,
one fundamental question yet to be addressed is: do angiogenic vessels in the ischemic
penumbra also show upregulation of fibronectin and its associated receptors? In the current
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study we have addressed this question by establishing cerebral ischemia using the middle
cerebral artery occlusion (MCA:O) model in mice, and then examined brains 7 days postischemia (the time window at which angiogenesis occurs), to characterize vascular
expression of the ECM proteins fibronectin and laminin, and their cell surface receptors.

MATERIALS AND METHODS
Animals
The present study was conducted in accordance with NIH guidelines for the care and use of
animals in research and under protocols approved by the Center for Laboratory Animal Care
at The University of Connecticut Health Center. Focal transient cerebral ischemia was
induced in male C57Bl6 mice (20-25g) by right middle cerebral artery occlusion (MCAO)
followed by reperfusion as described previously (Li et al. 2007). Mice were anesthetized
with 4% isoflurane mixed with room air and oxygen for induction and then maintained with
1-2% isoflurane/room air and oxygen mixture for all surgical procedures. At the end of
ischemia (90 minutes MCAO, the animal was briefly re-anesthetized, and reperfusion was
initiated by filament withdrawal. Cortical perfusion (Laser Doppler Flowmetry; LDF) were
evaluated throughout MCAO and early reperfusion as described previously (Li et al. 2007).
Behavioral measurements
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Neurological deficits (NDS) were scored immediately after MCA:O and at daily intervals up
to day 7 post-stroke. The scoring system was as follows: 0, no deficit; 1, forelimb weakness
and torso turning to the ipsilateral side when held by tail; 2, circling to affected side; 3,
unable to bear weight on affected side; and 4, no spontaneous locomotor activity or barrel
rolling (McCullough et al. 2005). Median NDS scores immediately after MCA:O, and after
3 days and 7 days post-ischemia were: 3 (range 3-4), 1 (range 1-2) and 1 (range 0-1)
respectively (n = 7). Weights of the mice at the same time-points were: 23.9 ± 0.87 g, 19.5 ±
1.54 g, and 21.8 ± 2.27 g, respectively.
Immunofluorescent studies and antibodies
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Seven days following MCA:O, mice were euthanized by perfusion with ice-cold saline, and
the brains rapidly dissected, equilibrated in 30 % sucrose for 3 days, and then stored at
−80°C. In parallel, untreated fresh brain slices, staining with TTC was performed, as
previously described (Liu et al. 2009), to demarcate the cerebral infarct. Immunofluorescent
(IF) studies were performed as previously described (Milner et al. 2008a) on 10 μm thick
frozen coronal sections. The following monoclonal antibodies were obtained from BD
Pharmingen (La Jolla, CA): rat monoclonal antibodies reactive for the α5 integrin subunit
(clone 5H10-27), α6 integrin (clone GoH3), Mac-1 (αMβ2 integrin, clone M1/70), CD31
(PECAM-1) (clone MEC13.3), and clone MECA-32, and the hamster monoclonal antibodies
reactive for the α5 (clone HMα5-1) and β3 integrin subunits (clone 2C9.G2). The mouse
monoclonal antibody reactive for β-dystroglycan (clone 43DAG/8D5) was obtained from
Novocastra (Newcastle, United Kingdom). The Cy-3 conjugated mouse monoclonal against
GFAP (clone G-A-5) was obtained from Sigma. Rabbit polyclonal antibodies against the
following proteins were used in this study: fibronectin (Sigma), laminin (Sigma), Ki67
(Vector Laboratories, Burlingame, CA). The Cy3-conjugated anti-rabbit and anti-hamster
secondary antibodies were obtained from Jackson Immunoresearch (West Grove, PA), and
the AlexaFluor 488-conjugated anti-rat, anti-mouse, and anti-rabbit secondary antibodies
were obtained from Invitrogen (Carlsbad, CA). TUNEL staining was performed using the
TUNEL kit (Invitrogen) according to the manufacturer’s instructions. Briefly, frozen brain
sections were processed for TUNEL-positive cells, and then counter-stained with the nuclear
marker Hoechst (Sigma).
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Quantification of the number of blood vessels positive for the different antigens was
performed by capturing images of the three regions of interest (contralateral hemisphere,
ischemic core and penumbra) with a X 20 objective on a Zeiss Axio Observer A1
microscope and Zeiss Axiocam MRC digital camera. Multiple images were taken of each
section, the number of positive events per field of view quantified in the three different
regions in each brain (n = 5 mice), and the results expressed as the mean ± SEM of the
number of antigen-positive events per field of view. Statistical significance was assessed by
using Student’s t test, in which p < 0.05 was defined as statistically significant.

RESULTS
Characterization of cell death and glial activation responses in the ischemic CNS
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C57BL/6 mice were subject to 90 minutes of ischemia by temporary occlusion of the middle
cerebral artery (MCA:O), followed by 7 days reperfusion. The size of the ischemic lesion in
these mice varied between 50-75% of the affected hemisphere (Figure 1A). The ischemic
hemisphere showed typical hallmark signs of severe focal cerebral ischemia, including
widespread areas of TUNEL-positive staining, indicating massive cell death (Figure 1B).
Within the ischemic hemisphere, astrocytes and microglia showed a marked glial activation
response (Figure 2A). GFAP immunofluoresence (IF) revealed an almost total absence of
astrocytes within the ischemic core, suggesting that most astrocytes within this area had
undergone cell death. In contrast, at the boundary between the ischemic core and penumbra,
a very intense GFAP reaction was apparent, with highly elevated levels of GFAP expression
within all astrocytes. Mac-1 IF demonstrated that within the ischemic penumbra and core,
microglia and/or macrophages showed increased cell density and increased levels of Mac-1
expression, typical of the activated phenotype (Hanisch and Kettenmann 2007).
Cerebral ischemia leads to alterations in blood vessel morphology and expression of
vascular markers
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Blood vessels were identified with the endothelial-specific marker CD31 (PECAM-1).
Compared with the contralateral hemisphere, the density of CD31-positive vessels within
the ischemic core was markedly reduced (20.5 ± 3.5 vessels/field compared with 47.5 ± 5.4
vessels/field in the contralateral hemisphere, p < 0.01), demonstrating that ischemia leads to
degeneration of blood vessels within the ischemic core. In contrast, vessel density in the
ischemic penumbra was significantly elevated (67.0 ± 8.1 vessels/field compared with 47.5
± 5.4 vessels/field in the contralateral hemisphere, p < 0.01), suggesting the growth of new
blood vessels in the ischemic penumbra (Figure 2B). Next, we examined vessel expression
of mouse endothelial cell antigen-32 (MECA-32), as this gives an indication of the
immaturity or leakiness of cerebral vessels. MECA-32 is not expressed by vessels in the
mature CNS, but is expressed by immature developing cerebral blood vessels (up to
embryonic day 15) before being switched off (Hallman et al. 1995), and is also induced on
adult cerebral vessels following endothelial cell disruption during infection (Engelhardt et
al. 1994). We have previously demonstrated that MECA-32 is transiently induced on
angiogenic vessels in the hypoxic adult CNS (Milner et al. 2008a). Consistent with previous
findings, blood vessels in the contralateral hemisphere were negative for MECA-32,
whereas in contrast, vessels in the ischemic core expressed high levels of this antigen
(Figure 2B). In addition, vascular expression of MECA-32 appeared to be inversely related
to the presence of GFAP expression, with the on-off border of both markers occurring at the
ischemic core/penumbra boundary. To more closely examine this relationship, we
performed dual-IF for GFAP and MECA-32. This revealed that vessels covered by GFAPpositive astrocyte processes were negative for MECA-32, while in contrast, vessels not
contacted by GFAP processes expressed high levels of MECA-32 (Figure 2C).
Exp Neurol. Author manuscript; available in PMC 2013 August 20.
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Cerebral vessels in the ischemic core show loss of the cell surface laminin receptors,
dystrogycan and α6β1 integrin, but a slower breakdown of vascular basement membrane
laminin
Previous studies of MCA:O in non-human primate and rat have shown that cerebral
ischemia leads to loss of basement membrane laminin and the laminin receptors, α6β1 and
dystroglycan from cerebral vessels (Hamann et al. 1995; Milner et al. 2008b; Tagaya et al.
2001). To investigate whether this also occurs in mice, we examined expression of these cell
adhesion molecules in this study. Interestingly, in our 7 day post-ischemic samples,
dystroglycan and the α6β1 integrin, which are expressed by all vessels in the non-ischemic
brain, were totally absent from vessels in the ischemic core (Figure 3A). This loss of
dystroglycan is entirely consistent with our previous observation that astrocyte foot
processes are the major source of dystroglycan on cerebral vessels (Milner et al. 2008b);
thus it follows that absence of astrocytes in the ischemic core would lead to disappearance of
dystroglycan from cerebral vessels. In contrast to the total loss of dystroglycan and α6β1
integrin, vessels in the ischemic core still expressed residual levels of laminin, though
staining revealed dilated dysmorphic vascular structures within the ischemic core. By
comparison, vessels in the ischemic penumbra showed no loss of expression of laminin,
α6β1 integrin or dystroglycan.
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Vascular remodeling in the ischemic penumbra is associated with proliferation of
endothelial cells, as well as proliferation of astrocytes and microglia
It is well established that an angiogenic response occurs within the ischemic penumbra
(Chen et al. 1994; Hayashi et al. 2003; Wei et al. 2001). To examine this response in the
mouse MCA:O model, we performed dual-IF for the endothelial marker CD31, and the cell
proliferation marker, Ki67. As shown in Figure 4A, whereas no Ki67-positive cells were
observed in the contralateral hemisphere, numerous CD31/Ki67 dual-positive cells were
seen in the ischemic penumbra, demonstrating brain endothelial cell proliferation and
angiogenic remodeling. This analysis also revealed many Ki67-positive cells that were
CD31-negative, suggesting the presence of other proliferating cell types, both in the
ischemic penumbra and core. To investigate whether astrocytes or microglia also proliferate
in the ischemic penumbra, we performed dual IF for GFAP/Ki67 and Mac-1/Ki67, which
confirmed the presence of proliferating astrocytes and microglia respectively (Figures 4B
and C).
Vessels in the ischemic penumbra show increased expression of fibronectin, and
enhanced endothelial expression of α5β1 and αvβ3 integrins
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We have shown that angiogenic vessels in the hypoxic CNS strongly upregulate expression
of fibronectin and its receptors, α5β1 and αvβ3 (Li et al. 2010; Milner et al. 2008a). Now,
we addressed whether a similar induction also occurs on angiogenic vessels in the ischemic
CNS. Consistent with previous findings, vessels in the contralateral hemisphere expressed
low levels of fibronectin. By comparison, vessels within the ischemic penumbra showed
markedly elevated levels of fibronectin expression (Figure 5A). Quantification revealed that
the number of fibronectin-positive vessels in the ischemic penumbra was significantly
greater than in the contralateral hemisphere (74 ± 10.3 fibronectin-positive vessels/field
compared with 19.5 ± 4.2 in the contralateral hemisphere, p < 0.001). In a similar manner,
while endothelial cells in the contralateral hemisphere expressed only low levels of α5β1
and no αvβ3 integrin, both fibronectin receptors were strongly upregulated on vessels in the
ischemic penumbra (50.5 ± 7.7 α5 integrin-positive vessels/field in the penumbra compared
with 11.8 ± 2.5 in the contralateral hemisphere, p < 0.001, and 18.5 ± 6.5 β3 integrinpositive vessels/field compared with 0.3 ± 0.5 in the contralateral hemisphere, p < 0.002),
(Figures 5B-D). This confirms that angiogenic vessels in the ischemic penumbra show clear
upregulation of fibronectin and its cognate receptors, α5β1 and αvβ3 integrins. We also
Exp Neurol. Author manuscript; available in PMC 2013 August 20.
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investigated the expression of fibronectin and the α5 and β3 integrins on vessels in the
ischemic core (Figure 6). This analysis was complicated by the fact that the ischemic core
was heavily infiltrated with inflammatory leukocytes expressing high levels of the α5
integrin that were surrounded by a fibronectin-rich ECM. In addition, while the β3 integrin
was not expressed at high levels by the inflammatory infiltrates, it was apparent that within
the ischemic core, the pattern of β3 staining was often more extensive than the CD31
staining, suggesting that some inflammatory cells transmigrating across the leaky damaged
vessels may also express the β3 integrin. Despite these complications, dual-IF with CD31/
fibronectin, CD31/α5 integrin, and CD31/β3 integrin suggested that vessels in the ischemic
core also express elevated levels of fibronectin and the α5 and β3 integrins, as shown in the
merged images in Figure 6.

DISCUSSION
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Focal cerebral ischemia results in a central ischemic core and a surrounding ischemic
periphery, or penumbra (Sharp et al. 2000). Ischemia within the core is so severe that most
of the cells in this area, including neurons and glia, die within days of the initial insult
(Dirnagl et al. 1999; Sharp et al. 2000). In the days following the ischemic insult, the
ischemic core expands in size as more cells undergo cell death, likely as a result of
secondary pathological mechanisms. While much effort has gone into understanding what
happens to neurons and glia following ischemia, less is known about the fate and pathogenic
mechanisms affecting vascular cells. This is fundamentally important for two reasons. First,
expansion of the ischemic territory that occurs in the days following the primary ischemic
insult (Liu et al. 2009) is likely a result of vascular breakdown and resulting edema. If the
vascular damage could be limited, then the size of ischemic infarct could be minimized.
Second, blood vessels in the ischemic penumbra launch an adaptive regenerative response,
sprouting new blood vessels as part of an intrinsic attempt to deliver blood to the oxygenstarved region (Chen et al. 1994; Hayashi et al. 2003; Wei et al. 2001). Thus it follows that
if this endogenous response could be enhanced, this would also minimize the size of
ischemic infarct.
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When contemplating the use of angiogenic therapy for stroke, two important issues should
be addressed. The first is to define the optimal time of treatment: is it best to treat before, or
immediately after ischemic stroke? Logic suggests that it would be optimal to promote
angiogenesis before the damage has been done, but in order to do that, it is necessary to
identify those patients who are at high risk of stroke. Such a group of patients might include
those who have recently suffered a transient ischemic attack (TIA), as this group show high
risk of subsequent stroke (Johnston et al. 2007; Rothwell et al. 2005). An alternative strategy
would be to apply angiogenic therapy immediately after stroke. The down-side of this
approach is that most ischemic neuronal cells die within days of ischemia, well before the
growth of new blood vessels occurs, thus limiting the protective impact of post-stroke
angiogenic therapy. However, post-ischemic therapy may have a role to play in promoting
repair and neurogenesis following ischemic damage, which by itself may still promote
clinical improvement. In addition to optimizing the timing of delivery, it is also imperative
that angiogenic therapy creates functional cerebral vessels without causing deleterious sideeffects, such as breakdown of blood-brain barrier (BBB) or hemorrhagic transformation,
such as that observed in angiogenic studies using VEGF (Zhang et al. 2000). Clearly, if
angiogenic therapy is to have any place in the clinic, these two issues need to be resolved
first.
Fibronectin is an important regulator of vascular remodeling, and recent data from our lab
suggests that fibronectin and its receptors play an important pro-angiogenic role in the CNS,
both during development and in the angiogenic response to hypoxia in the adult (Li et al.
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2010; Milner and Campbell 2002; Milner et al. 2008a). In light of this, the main aim of this
study was to determine whether angiogenic vessels in the ischemic penumbra show
upregulation of fibronectin and the α5β1 and αvβ3 integrins. Our main findings were as
follows: (i) blood vessels in the ischemic core show strong induction of MECA-32, a marker
of immature/leaky cerebral endothelium, and this induction correlates with loss of coverage
from GFAP-positive astrocyte endfeet, (ii) vessels within the ischemic core degenerate and
lose expression of the adhesion molecules laminin, dystroglycan, and α6β1 integrin, (iii) the
appearance of CD31/Ki67 dual-positive cells in the ischemic penumbra demonstrates
angiogenic vessels in this region, and (iv) vessels in the ischemic penumbra show marked
upregulation of fibronectin and the fibronectin receptors, α5β1 and αvβ3 integrins.
Blood vessels in the ischemic core express MECA-32, a marker of immature cerebral
endothelium, and this correlates with loss of vessel coverage by astrocyte endfeet
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MECA-32 is a marker of immature or leaky brain endothelium. During development,
MECA-32 labels brain endothelial cells only up to embryonic day 15 (E15) (Hallman et al.
1995). It also labels angiogenic endothelial cells in the adult CNS following cerebral
hypoxia (Milner et al. 2008a) or after bacterial infection (Engelhardt et al. 1994). In this
study, we determined that a large number of vessels within the ischemic core expressed
MECA-32 at high levels, and that MECA-32-positive vessels extended up to the ischemic
border. Interestingly, MECA-32 and GFAP expression displayed a mutually exclusive
relationship, suggesting that cerebral vessels denuded of astrocyte contact lose their mature
blood-brain barrier (BBB) properties, and re-express MECA-32. This would be consistent
with the seminal work of Janzer and Raff, who demonstrated that astrocyte contact is
essential for cerebral vessels to acquire BBB-specific properties of mature brain vessels
(Janzer and Raff 1987). Our work suggests that MECA-32 is a good marker of brain vessels
that have lost astrocyte contact, and would also explain why MECA-32 is expressed only
transiently during the physiological adaptive angiogenic response in the hypoxic CNS
(Milner et al. 2008a). During this response, remodeling cerebral vessels only momentarily
lose their astrocyte contact, before re-adopting mature BBB characteristics. This is in
contrast to vessels in the ischemic core, which lose astrocyte contact permanently, resulting
in strong and sustained expression of MECA-32. Taken together, this evidence suggests that
astrocytes play a central role in maintaining vascular integrity in the CNS, raising the notion
that protecting astrocytes might be key in the treatment of ischemic stroke.
Differential loss of laminin and laminin receptors from cerebral vessels in the ischemic
core
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Our finding that blood vessels in the ischemic core show reduced expression of laminin and
its cognate receptors, α6β1 integrin and dystroglycan are largely consistent with previous
studies of MCA:O in other species (Hamann et al. 1995; Milner et al. 2008b; Tagaya et al.
2001). However, it should be noted that in our study we observed a differential loss of
adhesion molecules in the ischemic core, with a total absence of dystroglycan and
α6β1integrin, but only a partial reduction in laminin, 7 days post-ischemia. Several
explanations may account for this. First, the most likely reason is that as blood vessels
degenerate, endothelial cells undergo cell death, with concomitant loss of cell surface
receptors, including dystroglycan and integrins. In contrast, ECM components of the
vascular basal lamina including laminin are not destroyed immediately upon cell death, but
remain for extended time in the form of a dysfunctional vascular scaffold. Second,
dystroglycan and α6β1 integrin may be more sensitive to the effect of destructive proteases,
than laminin. This would be consistent with our recent findings that dystroglycan expression
is rapidly lost in the ischemic core of the non-human primate, in an MMP-dependent manner
(Milner et al. 2008b). Third, taken with our recent observation that the vast majority of
dystroglycan is expressed by astrocyte end-feet (Milner et al. 2008b), and our current
Exp Neurol. Author manuscript; available in PMC 2013 August 20.
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finding, that by 7 days post-ischemia, the ischemic core is almost entirely devoid of
astrocytes, it seems entirely feasible that loss of dystroglycan immunoreactivity directly
reflects the absence of astrocytes in this region.
Induction of fibronectin and the α5β1 and αvβ3 integrins on angiogenic vessels in the
ischemic penumbra
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An angiogenic response in the ischemic penumbra has been well described, both following
stroke in humans (Krupinski et al. 1994) or experimental focal cerebral ischemia in animal
models (Chen et al. 1994; Hayashi et al. 2003; Wei et al. 2001). One of the primary aims of
this study was to determine whether the angiogenic vessels show induction of fibronectin
and associated cell surface receptors, as has been demonstrated on angiogenic vessels in the
hypoxic CNS. We found that this was indeed the case, with a large number of vessels in the
ischemic penumbra showing markedly increased levels of expression of fibronectin and the
α5β1 and αvβ3 integrins. These findings are consistent with previous studies showing that
the αvβ3 integrin is induced on vessels in the post-ischemic CNS, both in non-human
primate (Okada et al. 1996) and rat (Wei et al. 2001). This supports the growing concept that
fibronectin provides an important angiogenic drive in the CNS, via the endothelial cell
surface receptors α5β1 and αvβ3. Recent studies have demonstrated an important
instructive role for β1 integrin signalling in post-ischemic angiogenesis (Lathia et al. 2010).
Taken with our recent demonstration that the α5β1 integrin is a key mediator of cerebral
angiogenesis (Li et al, manuscript in preparation), this strengthens the concept that
manipulation of the α5 integrin signaling pathway may provide a novel approach to promote
angiogenesis in the ischemic CNS. Interestingly, vessels in the ischemic core also expressed
high levels of fibronectin and its integrin receptors. This most likely reflects expansion of
the ischemic territory with time, i.e.: yesterday’s ischemic penumbra is today’s ischemic
core. This is consistent with the idea that a hypoxic insult promotes endothelial expression
of fibronectin and its integrin receptors, and that whether this angiogenic switch results in
successful production of new vessels depends on how far the ischemic core expands. If the
vessels become swallowed up by the expanding ischemic core, the vessels will breakdown
and degenerate. However, if the vessels remain outside the core, they have the potential to
form new functional vessels.
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Previous studies have highlighted an important protective role for fibronectin following
cerebral ischemia and trauma. Deletion of plasma fibronectin in transgenic mice led to a
worse clinical outcome following cerebral ischemia, and this correlated with increased
levels of neuronal death (Sakai et al. 2001). In another study, brain trauma induced greater
neuronal death and lesion size in mice deficient in plasma fibronectin (Tate et al. 2007). The
authors of both these studies suggested that plasma-derived fibronectin leaks into cerebral
tissue following injury and BBB breakdown, providing a survival cue for neurons. Our
studies provide an alternative explanation for these experiments by suggesting that
fibronectin plays an important role in stimulating post-ischemic angiogenesis, which would
provide an indirect protective effect on neuronal survival. In summary, we have
demonstrated that fibronectin and the associated endothelial fibronectin receptors, α5β1 and
αvβ3 integrins, are strongly upregulated on angiogenic vessels in the ischemic penumbra. In
the next set of experiments, we will test the functional significance of this induction by
determining whether cerebral angiogenesis is attenuated in transgenic mice lacking
endothelial expression of the α5β1 or αvβ3 integrins.
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•

Cerebral ischemia leads to angiogenesis in the ischemic penumbra.

•

We study the molecular mechanisms that underlie this process.

•

Angiogenic vessels upregulate fibronectin and integrin receptors, α5β1 and
αvβ3.

•

This suggests that fibronectin may drive cerebral angiogenesis.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Exp Neurol. Author manuscript; available in PMC 2013 August 20.

Li et al.

Page 13

NIH-PA Author Manuscript
Figure 1.
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Examination of cell death within the cerebral infarct seven days after middle cerebral artery
occlusion (MCA:O). A. TTC staining differentiates the infarct (white) from viable tissue
(red). Boxes outline the regions of interest, including the ischemic core (IC), ischemic
penumbra (P), and the contralateral hemisphere (CL). B. TUNEL staining reveals massive
cell death within the ischemic core. Scale bar = 50 μm.
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Figure 2.

Glial and vascular activation responses seven days post-focal cerebral ischemia. White lines
demarcate the ischemic core/penumbra boundary. A. GFAP immunofluorescence (IF)
revealed a paucity of astrocytes within the ischemic core, but a marked astrocytic activation
within the ischemic penumbra. Mac-1 IF demonstrated a microglia/macrophage activation
response in the ischemic core and penumbra. Scale bar = 50 μm (inserts, scale bar = 15 μm).
B. CD31 IF showed a reduction in vessel density within the ischemic core, but an increased
density in the ischemic penumbra. MECA-32 IF revealed no staining in the contralateral
hemisphere, but strong induction on vessels in the ischemic core and penumbra. Scale bar =
50 μm. C. Dual-IF with MECA-32 and GFAP revealed an exclusive relationship between
the two markers; astrocyte-ensheathed vessels never expressed the MECA-32 antigen, but
vessels denuded of astrocyte contact showed strong MECA-32 induction. Scale bar = 100
μm.
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Figure 3.

The influence of focal cerebral ischemia on vascular expression of laminin and laminin
receptors. A. Seven days following cerebral ischemia, expression of the laminin receptors
dystroglycan and α6 integrin was totally eliminated from vessels in the ischemic core.
Laminin immunoreactivity was still present on vessels in the core region, but the staining
revealed dilated degenerating vessels. Scale bar = 50 μm. B. Quantification of vascular
expression of laminin and its receptors. Note the total loss of β-dystroglycan and α6 integrin
expression from vessels in the ischemic core, but the delay in loss of laminin.
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Figure 4.

Identification of proliferating cells in the ischemic penumbra seven days following focal
cerebral ischemia. Dual-IF with cell-specific markers and the proliferation marker Ki67 was
performed on frozen sections of ischemic penumbra or contralateral hemisphere to identify:
(A) endothelial cells (CD31), (B) astrocytes (GFAP), or (C) microglia/macrophages
(Mac-1). White lines demarcate the ischemic core/penumbra boundary. Scale bar = 25μm
(inserts = 7.5μm). Note that no cell proliferation was detected in the contralateral
hemisphere. In contrast, the ischemic penumbra contained proliferating endothelial cells,
astrocytes and microglia/macrophages.
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Figure 5.

Upregulation of fibronectin and its integrin receptors on cerebral vessels in the ischemic
penumbra seven days after focal cerebral ischemia. Frozen sections of ischemic penumbra or
contralateral hemisphere were examined for vascular expression of: (A) fibronectin, (B) α5
integrin, or (C) β3 integrin. Scale bar = 50 μm. Note that while few vessels in the
contralateral hemisphere expressed fibronectin or its receptors, vessels in the ischemic
penumbra strongly upregulated fibronectin and the α5 and β3 integrins (D).
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Figure 6.
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Examination of vascular expression of fibronectin and its receptors in the ischemic core
seven days after focal cerebral ischemia. Frozen sections encompassing the ischemic core
and penumbra were examined for vascular expression of fibronectin, α5 integrin, or β3
integrin. White lines demarcate the ischemic core/penumbra boundary. Scale bar = 100 μm.
Note that inflammatory leukocytes in the ischemic core expressed high levels of the α5
integrin and were surrounded by a fibronectin-rich ECM. In addition, vessels in the ischemic
core expressed elevated levels of fibronectin and the α5 and β3 integrins, as demonstrated in
the merged images.
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